Menu

PRESS RELEASES


Björn Westberg to join BONESUPPORT™ as Chief Financial Officer

21st December

BONESUPPORT confirms election of Dr. Håkan Björklund as Chairman of the Board

16th December

Richard Davies Wins “Best CEO in the Biomaterials Industry” Award from European CEO Magazine

13th December

BONESUPPORT™ Announces Key Corporate Appointment To Drive Growth in North America

7th November

BONESUPPORT™ Raises $37 Million (SEK 327 million) to Drive Product Sales and Deliver Further Value From CERAMENT® Injectable Drug Eluting Bioceramic Platform

27th October

BONESUPPORT™‘s CERAMENT®|G Highly Effective Adjunct in the Single Stage Surgical Management of Chronic Osteomyelitis

1st September

BONESUPPORT™‘s CERAMENT®|G and CERAMENT® V to be Featured Extensively at the 35th Annual Meeting of the European Bone & Joint Infection Society (EBJIS) in Oxford, UK

30th August

BONESUPPORT™ Receives FDA Approval to Initiate IDE Clinical Study

9th August

BONESUPPORT™ Announces Nature Publication of Pre-Clinical Study Highlighting CERAMENT®’s Attractive Bone Remodeling Properties and as a Local Drug Delivery Platform for Bone Disease

1st June

BONESUPPORT® Announces Availability in Europe of CERAMENT™|G in 5 mL Volume to Address Growing Market Demand

1st March

BONESUPPORT™ Reports Expansion of Company's CERAMENT® Drug Eluting Procedure Registry

2nd February

BONESUPPORT™ Announces Appointment of Life Sciences Industry Veteran, Richard Davies, as New Chief Executive Officer

22nd January

BONESUPPORT™ Announces 20,000 Patients Now Treated with CERAMENT®

11th January

BONESUPPORT™ Announces CERAMENT® Focused Research Collaboration with Rigshospitalet, Copenhagen University Hospital

7th January

BONESUPPORT™ Announces Positive Data Highlighting the Use of CERAMENT®|G in the Management of Osteomyelitis in the Infected Diabetic Foot

5th January

Change in number of shares and votes in BONESUPPORT HOLDING AB (publ)

29th December 2017

BONESUPPORT™ ACHIEVES AIM OF RECRUITING 136 PATIENTS INTO THE CERTiFy STUDY COMPARING CERAMENT®|BONE VOID FILLER WITH AUTOGRAFT

13th December 2017

BONESUPPORTTM OPENS ITS NEW HEAD QUARTERS

12th December 2017

Change in number of shares and votes in BONESUPPORT HOLDING AB (publ)

30th November 2017

BONESUPPORT HOLDING AB (publ) NOMINATION COMMITTEE FOR THE ANNUAL GENERAL MEETING 2018 APPOINTED

22nd November 2017

BONESUPPORTTM SIGNS COMMERCIALIZATION AGREEMENT FOR THE ITALIAN MARKET

20th November 2017

BONESUPPORTTM - CERAMENT® G’s POTENTIAL TO PREVENT AND MANAGE BIOFILM-RELATED BONE INFECTIONS HIGHLIGHTED IN NEW HIGH-PROFILE PUBLICATION

14th November 2017

BONESUPPORT HOLDING AB (publ) – Interim Report – January – September 2017

2nd November 2017

Change in number of shares and votes in BONESUPPORT HOLDING AB (publ)

31st October 2017

BONESUPPORT HOLDING AB (publ) – Q3 2017 Interim Report – invitation to conference call and webcast

19th October 2017

BONESUPPORTTM APPOINTS HELENA L BRANDT AS HEAD OF HUMAN RESOURCES

13th October 2017

BONESUPPORTTM – First Patient Recruited in Study Evaluating CERAMENT® G and CERAMENT® V in Patients Undergoing Hip and Knee Arthroplasty Revisions

9th October 2017

Change in number of shares and votes in BONESUPPORT HOLDING AB (publ)

29th September 2017

BONESUPPORT™ – DATA PRESENTED AT THE EUROPEAN ORTHOPAEDIC RESEARCH SOCIETY MEETING HIGHLIGHTS CERAMENT® BONE VOID FILLER (BVF) ABILITY TO ELUTE DRUGS WITH THE POTENTIAL TO ENHANCE BONE GROWTH

20th September 2017

BONESUPPORT APPOINTS JERRY CHANG AS EXECUTIVE VICE PRESIDENT OF RESEARCH & DEVELOPMENT

19th September 2017

BONESUPPORT™ SIGNS COMMERCIALIZATION AGREEMENT FOR THE FRENCH MARKET

7th September 2017

Change in number of shares and votes in BONESUPPORT HOLDING AB (publ)

31st August 2017

BONESUPPORT HOLDING AB (publ) - Interim Report January - June 2017

17th August 2017

BONESUPPORT™ - Q2 2017 Interim Report – invitation to conference call and webcast

11th August 2017

Change in number of shares and votes in BONESUPPORT HOLDING AB (publ)

31st July 2017

Exercise of over-allotment option and end of the stabilization period

21st July 2017

Stabilization notice

17th July 2017

BONESUPPORT™ - Pipeline Project Targeting Bioceramics Capable of Enhancing Bone Growth Awarded SEK 8 million Grant from Vinnova Sweden

12th July 2017

Stabilization notice

5th July 2017

Change in number of shares and votes in BONESUPPORT HOLDING AB (publ)

30th June 2017

Final price in BONESUPPORT™’s initial public offering set at SEK 29 per share – trading on Nasdaq Stockholm commences today

21st June 2017

BONESUPPORT™ Announces First Patient Enrolled in FORTIFY Trial with CERAMENT®|G, a novel injectable, antibiotic-eluting bone graft substitute

22nd May

Lennart Johansson to join BONESUPPORT™ Board of Directors

28th April

BONESUPPORT™ appoints Michael Diefenbeck as Chief Medical Officer

11th April

BONESUPPORT™ Founder Lars Lidgren Receives the 2017 OREF Clinical Research Kappa Delta Award

16th March

BONESUPPORT™ Extends U.S. Distribution Agreement for CERAMENT®|BONE VOID FILLER

14th March

BONESUPPORT CEO to present at the Medtech Showcase 2017, in conjunction with the 9th Annual Biotech Showcase™

6th January

Change in number of shares and votes in BONESUPPORT HOLDING AB (publ)

28th December 2018

Change in number of shares and votes in BONESUPPORT HOLDING AB (publ)

30th November 2018

BONESUPPORT - POSITIVE RESULTS FROM THE CERTiFy STUDY COMPARING CERAMENT®|BONE VOID FILLER WITH AUTOGRAFT

19th November 2018

BONESUPPORT HOLDING AB (publ) – Interim Report

7th November 2018

BONESUPPORT HOLDING AB (publ) – Q3 2018 Interim Report – invitation to conference call and webcast

1st November 2018

BONESUPPORT starts selling CERAMENT® BONE VOID FILLER Direct in the US via its own New Distributor Network

22nd October 2018

BONESUPPORT to Showcase CERAMENT® BONE VOID FILLER at Two Upcoming US Orthopedic Conferences

8th October 2018

Change in number of shares and votes in BONESUPPORT HOLDING AB (publ)

28th September 2018

BONESUPPORT highlights significant strategic progress at Capital Market Days in Stockholm and London

19th September 2018

BONESUPPORT to be Featured at the Annual Meeting of the European Bone & Joint Infection Society (EBJIS)

6th September 2018

Invitation BONESUPPORT Capital Markets Days

5th September 2018

Save the date: BONESUPPORT Capital Markets Days to be held in Stockholm and London

24th August 2018

BONESUPPORT - CERAMENT® G Approved by Health Canada

16th August 2018

BONESUPPORT Signs Agreement with MTF Biologics to Expand US Product Offering

2nd August 2018

BONESUPPORT HOLDING AB (publ) – Interim Report

26th July 2018

Q2 2018 Interim Report – invitation to conference call and webcast

23rd July 2018

BONESUPPORT appoints Michael Diefenbeck as Head of Research & Development, Medical and Clinical Affairs

18th July 2018

Håkan Johansson to start as BONESUPPORT’s CFO at the end of 2018

4th July 2018

Change in number of shares and votes in BONESUPPORT HOLDING AB (publ)

29th June 2018

BONESUPPORT provides update on US orders of CERAMENT BVF

21st June 2018

BONESUPPORT to significantly expand its European sales organization

29th May 2018

BONESUPPORT Signs Strategic Agreement with Collagen Matrix, Inc. to Expand Product Offering in the US

24th May 2018

BULLETIN FROM THE ANNUAL SHAREHOLDERS’ MEETING IN BONESUPPORT HOLDING AB ON 22 MAY 2018

22nd May 2018

BONESUPPORT creates its own US Commercial Platform

17th May 2018

BONESUPPORT HOLDING AB (Publ) – Q1 Interim Report

4th May 2018

BONESUPPORT HOLDING AB (publ) publishes Annual Report 2017

30th April 2018

BONESUPPORT HOLDING AB (publ) – Q1 2018 Interim Report – invitation to conference call and webcast

27th April 2018

NOTICE OF ANNUAL SHAREHOLDERS’ MEETING IN BONESUPPORT HOLDING AB

20th April 2018

BONESUPPORT™ – Positive clinical data for CERAMENT® G in infection management presented at BLRS 2018

21st March 2018

BONESUPPORT’s New CEO Purchases Shares

13th March 2018

BONESUPPORTTM to present at Orthopaedic Research Society (ORS) 2018 Annual Meeting

9th March 2018

BONESUPPORT™ to present at Canaccord Musculoskeletal Conference

5th March 2018

Change in number of shares and votes in BONESUPPORT HOLDING AB (publ)

28th February 2018

BONESUPPORT™ HOLDING AB (Publ) – Q4 and 2017 Year-End Report – January – December

20th February 2018

BONESUPPORT HOLDING AB – Year-end Report January-December 2017 – invitation to conference call and webcast

6th February 2018

BONESUPPORT™ repays outstanding loan from Kreos

1st February 2018

Change in number of shares and votes in BONESUPPORT HOLDING AB (publ)

31st January 2018

Emil Billbäck appointed CEO of BONESUPPORT

23rd January 2018

PUBLICATION HIGHLIGHTS A NOVEL CERAMENT® CARRIER WITH BONE ACTIVE AGENTS ENHANCING BONE FORMATION

22nd January 2018

Change in number of shares and votes in BONESUPPORT HOLDING AB (publ)

31 July 2019

BONESUPPORT HOLDING AB (publ) – Publishes Q2 2019 Interim report

25 July 2019

Item affecting comparability in Q2 2019

19 July 2019

BONESUPPORT HOLDING AB (publ) – Q2 2019 Interim Report – invitation to conference call and webcast

18 July 2019

BULLETIN FROM THE ANNUAL SHAREHOLDERS’ MEETING IN BONESUPPORT HOLDING AB ON 14 MAY 2019

14th May 2019

BONESUPPORT HOLDING AB (publ) – Published Q1 2019 Interim report

2nd May 2019

BONESUPPORT HOLDING AB (publ) – Q1 2019 Interim Report – invitation to conference call and webcast

25th April 2019

BONESUPPORT - Change in the management team

24th April 2019

BONESUPPORT HOLDING AB (publ) publishes Annual Report 2018

17th April 2019

BONESUPPORT will publish quarterly report earlier than previously communicated

16th April 2019

NOTICE OF ANNUAL SHAREHOLDERS’ MEETING IN BONESUPPORT HOLDING AB

12th April 2019

ACTIVE REMODELING OF CERAMENT® INTO HUMAN BONE CONFIRMED IN UK STUDY

10th April 2019

Change in number of shares and votes in BONESUPPORT HOLDING AB (publ)

29th March 2019

BONESUPPORT LAUNCHING A NEW PRODUCT - BONIFY - US PRODUCT PORTFOLIO EXPANSION

13th March 2019

Issue and repurchase of series C shares for share saving programs

1st March 2019

BONESUPPORT HOLDING AB (publ) – Full Year Report 2018

27th February 2019

BONESUPPORT – Publication of a clinical study highlighting Vancomycin release from CERAMENT® V in major hip surgery

22nd February 2019

BONESUPPORT HOLDING AB (publ) – Invitation to conference call in connection of the Full Year Report 2018

20th February 2019

Correction of error Q3 (18) report

13th February 2019

BONESUPPORT – Publication of pre-clinical study highlighting unique bone remodeling qualities of CERAMENT® in large bone defects

8th February 2019

BONESUPPORTTM and Lund University to present at Orthopaedic Research Society (ORS) 2019 Annual Meeting

1st February 2019

BONESUPPORT appoints Annelie Aava Vikner as Executive Vice President Global Marketing & Communications

4th January 2019

BONESUPPORT™ Announces Appointment of Life Sciences Industry Veteran, Richard Davies, as New Chief Executive Officer

Mr. Davies Brings over 25 Years of Life Sciences Industry Experience to BONESUPPORT™

Current Chief Executive Officer, Lloyd Diamond, to Transition to Role of Chief Business Officer

Lund, Sweden, (PRNEWSWIRE) January 22, 2016 – BONESUPPORT™, an emerging leader in both injectable bone substitutes and innovative drug eluting bone scaffold technology for orthopedic trauma, bone infections and instrument augmentation related to orthopedic surgery, announced today that the Company has appointed Richard Davies as BONESUPPORT™’s new Chief Executive Officer, effective immediately. Mr. Davies is a senior commercial leader in the life sciences industry with 25 years of global experience in all aspects of sales / marketing and country / regional leadership, a track record of devising and executing growth strategies and delivering successful results in complex situations.

BONESUPPORT™’s current Chief Executive Officer, Lloyd Diamond, will transition to the role of Chief Business Officer, effective immediately. Mr. Diamond will re-locate back to the U.S., establishing an executive level presence for the Company’s largest market. During his time with BONESUPPORT™, Mr. Diamond secured an important distribution agreement in the U.S. with the world’s largest orthopedic market player, Zimmer Biomet, and transformed the Company from a Research and Development organization to a fully commercial group, with more than 20,000 CERAMENT™ procedures performed worldwide.

“I am proud of the transition BONESUPPORT™ has made from an R&D organization to a global commercial company in the four years I have had the pleasure of serving as CEO,” said Mr. Diamond. “My new role as Chief Business Officer will allow me to focus on further driving CERAMENT™ commercial growth, particularly in the U.S. market."

Mr. Davies previously spent nearly four years at Hospira, where he served as Chief Commercial Officer. While at Hospira, he drove growth, globalization and modernization across the business. Mr. Davies’ efforts led the company to an acceleration of revenue growth to 12% per year. Hospira was acquired by Pfizer at the end of 2015. Prior to Hospira, Mr. Davies spent nine years in increasingly senior leadership positions at Amgen in Europe, Australia and the U.S. His roles encompassed a start up of clinical and commercial operations in CEE, leadership of Australia and New Zealand and leadership of the U.S. Inflammation sales group, commercializing Enbrel, the most prescribed biologic medicine in the U.S. at that time. His most recent position at Amgen was General Manager, Japan and Asia Pacific.  Mr. Davies began his career at Eli Lilly, spending 13 years in increasingly senior positions.

“First, on behalf of the entire Board, I’d like to thank Lloyd for his dedication and numerous achievements as BONESUPPORT™’s CEO over the past four years,” said Oern R. Stuge, M.D., BONESUPPORT™’s Chairman of the Board. “We are delighted to welcome Richard to BONESUPPORT™. His vast pharmaceutical experience will be key to leveraging the drug eluting capabilities of CERAMENT™. I look forward to working closely with Richard as we focus on the many opportunities ahead of BONESUPPORT™ in the coming years.”

“I am pleased to be joining BONESUPPORT™ as CEO at such a critical juncture in the Company’s history,” said Mr. Davies. “The technology BONESUPPORT™ has developed offers important health benefits to patients and represents significant upside value potential for investors. Lloyd has done a tremendous job in advancing the Company and I look forward to working with him and the team to continue to accelerate this growth.”

Mr. Davies is currently Chairman of the Board of Alvotech Iceland and has previously served on the Board of Zydus Hospira Oncology Products Ltd., and of several trade associations in Poland and Australia. He holds a B.Sc. in Applied Chemistry from Portsmouth University, and an MBA from Warwick Business School.

Ends

Notes to Editor

 

About BONESUPPORT™

BONESUPPORT AB has developed CERAMENT™ as an innovative range of radiopaque injectable osteoconductive bioceramic products that have a proven ability to heal defects by remodeling to host bone in six to twelve months. Our products are effective in treating patients with fractures and bone voids caused by trauma, infection, disease or related surgery. Our lead product, CERAMENT™|BONE VOID FILLER (BVF) addresses important issues facing health care providers, such as avoiding hospital readmissions and revision surgery that result from failed bone healing and infection caused by residual bone voids. CERAMENT|BVF is commercially available in the U.S., EU, S.E. Asia and the Middle East.

CERAMENT's distinctive properties as a drug eluting material have been validated in clinical practice by CERAMENT™|G and CERAMENT™ V, the first CE-marked injectable antibiotic eluting bone graft substitutes. These products provide local sustained delivery of gentamicin and vancomycin, respectively. The local delivery feature enables an initial high concentration of antibiotics to the bone defect and then a longer sustainable dose above the minimal inhibitory concentration (MIC) to protect bone healing and promote bone remodeling.

CERAMENT|G and CERAMENT™ have demonstrated good results in patients with problematic bone infections including osteomyelitis. They are also used prophylactically in patients who are at risk for developing infection. CERAMENT|G and CERAMENT™ V are available in the EU.

BONESUPPORT AB was founded in 1999 by Prof. Lars Lidgren, an internationally respected scientist who has been the President of various musculoskeletal societies. BONESUPPORT’s mission is to bring people with bone and joint diseases back to an active life. The company is based in Lund, Sweden.

bonesupport.com

BONESUPPORT™ is a registered trademark.

Contact Information

Citigate Dewe Rogerson

David Dible, Andrea Bici, Mark Swallow

+44 (0)20 7282 2949/1050/2948

Downloads

Press release PDF (112.24 KB)

BONESUPPORT, Fri Aug 2, 2019

@MSIS 2019 CERAMENT Bone Void Filler injectable bone graft substitute remodels to bone 6-12 months. Meet… https://t.co/vbLgu854rt

BONESUPPORT, Fri Aug 2, 2019

@BONESUPPORT_AB is exhibiting at the MSIS congress NYC. Hear more about CERAMENT G resorbable injectable antibiotic… https://t.co/JJ8wURMyNT

BONESUPPORT, Thu Mar 21, 2019

Busy first day at @OBIC! Come a meet BONESUPPORT tomorrow and learn more about CERAMENT G and V. https://t.co/Ulc3BGPgIF